The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Open-label, single-group Phase II fMRI study of a single 25 mg oral psilocybin dose in 20 participants with treatment-resistant major depressive disorder to assess changes in rumination and neural correlates.

Primary purpose is basic science; outcomes include neuroimaging measures of self-related processing, clinical scales (HAM-D-17), and safety assessments.